Controversies in the Treatment of Lung Cancer

12th International Symposium on Special Aspects of Radiotherapy, Berlin, October 2008

Editor(s): Heide J. (Berlin) 
Schmittel A. (Berlin) 
Kaiser D. (Berlin) 
Hinkelbein W. (Berlin) 
Table of Contents
Vol. 42, No. , 2010
Section title: NSCLC: Stage I/II Disease
Heide J, Schmittel A, Kaiser D, Hinkelbein W (eds): Controversies in the Treatment of Lung Cancer. Front Radiat Ther Oncol. Basel, Karger, 2010, vol 42, pp 87–93

Radiation Therapy for Early Stage (I/II) Non-Small Cell Lung Cancer

Jeremic B. · Casas F. · Wang L. · Perin B.
aDivision of Human Health (NAHU), Applied Radiobiology and Radiotherapy (ARBR) Section, International Atomic Energy Agency (IAEA), Vienna, Austria; bDepartment of Radiation Oncology, University Clinic, Barcelona, Spain; cChinese Medical Academy of Sciences, Beijing, China; dInstitute of Lung Disease, Sremska Kamenica, Serbia

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


For patients with early (stage I/II) non-small cell lung cancer (NSCLC) surgery is considered as the standard treatment of choice, although recent data on additional chemotherapy (CHT) showed that it may be beneficial in this setting. There is, however, a subset of patients that never undergo surgery. These patients are considered technically operable, but medically inoperable, due to existing comorbidities. In addition, frequently elderly patients with early NSCLC are denied surgery due to expected peri- and/or postoperative complications. Finally, in recent years there has been an increase in the incidence of patients refusing surgery. For all these patients, radiation therapy (RT) was traditionally considered as the standard treatment option. Data accumulated over the last 5 decades showed that RT alone can produce median survival times of up to > 30 months and 5-year survival of up to 30%. When cancer-unrelated deaths were taken into account, cause-specific survival rates were usually higher for some 10–15%. Accumulated experience seems to suggest that doses of at least 65 Gy with standard fractionation or its equivalent when altered fractionation is used are necessary for control of the disease. Smaller tumors seem to have favorable prognosis, while the issue of elective nodal RT continues to be controversial. Patterns of failure have clearly identified local failure as the predominant one. Although a number of potential pretreatment patient- and tumor-related prognostic factors have been examined, none has been shown to clearly influenced survival. Toxicity was usually low.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Jeremic B, Classen J, Bamberg M: Radiation therapy alone in technically operable, medically inoperable early stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:119-130
  2. Zhang HX, Yin WB, Zhang LJ: Curative radiotherapy of early operable non-small cell lung cancer. Radiother Oncol 1989;14:89-94
  3. Morita K, Fuwa N, Suzuki Y: Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: retrospective analysis of 149 patients. Radiother Oncol 1997;42:31-36
  4. Jeremic B, Shibamoto Y, Acimovic LJ, Milisavljevic S: Hyperfractionated radiotherapy alone for clinical stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1997;38:521-525
  5. Jeremic B, Shibamoto Y, Acimovic LJ, Milisavljevic S: Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer. Radiother Oncol 1999;51:141-145
  6. Cheung PCF, Mackillop WJ, Dixon P: Involved-field radiotherapy alone for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2000;48:703-710
  7. Sandler HM, Curran WJ, Jr, Turrisi AT, III: The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non- small cell lung cancer. Int J Radiat Oncol Biol Phys 1990;19:9-13
  8. Kaskowitz L, Graham MV, Emami B: Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993;27:517-523
  9. Krol ADG, Aussems P, Noordijk EM: Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation?. J Radiat Oncol Biol Phys 1996;34:297-302
  10. Sibley GS, Jamieson TA, Marks LB: Radiotherapy alone for medically inoperable stage I non-small cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 1998;40:149-154
  11. Slotman BJ, Karim ABMF: Curative radiotherapy for technically operable stage I nonsmall cell lung cancer. Int JRadiat Oncol Biol Phys 1994;29:33-37
  12. Noordijk EM, van den Poest Clement E, Hermans J: Radiotherapy as an alternative to surgery in elderly patients with respectable lung cancer. Radiother Oncol 1988;13:83-89
  13. Slotman BJ, Antonisse IE, Njo KH: Limited field irradiation in early stage (T1-2 N0) non-small cell lung cancer. Radiother Oncol 1996;41:41-44
  14. Mountain CF: A new international staging system for lung cancer. Chest 1986;89:225S-233S
  15. Mountain CF: Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717
  16. Gauden S, Ramsay J, Tripcony L: The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest 1995;108:1278-1282
  17. Dosoretz DE, Katin MJ, Blitzer PH: Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys 1992;25:3-9
  18. Hayakawa K, Mitsuhashi N, Nakajima N: Radiation therapy for stage III epidermoid carcinoma of the lung. Lung Cancer 1992;8:213-224
  19. Rosenthal SA, Curran WJ, Jr, Herbert SH: Clinical stage II non-small cell lung cancer treated with radiation therapy alone: the significance of clinically staged ipsilateral hilar adenopathy (N1 disease). Cancer 1992;70:3410-3417
  20. Dosoretz DE, Galmarini D, Rubenstein JH: Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys 1993;27:507-516
  21. Ono R, Egawa S, Suemasu K: Radiotherapy in inoperable stage I lung cancer. Jpn J Clin Oncol 1991;21:125-128
  22. Jeremic B: Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in non-small cell lung cancer (NSCLC): enough to convert no-elective into elective nodal irradiation (ENI)?. Radiother Oncol 2004;71:123-125
  23. Jeremic B: Low incidence of isolated nodal failures after involved field radiation therapy (IFRT) for nonsmall cell lung cancer (NSCLC): blinded by the light?. J Clin Oncol 2007;25:5543-5545
  24. Belderbos JSA, Kepka L, Kong FM, Martel MK, Videtic GMM, Jeremic B: Report from the International Atomic Energy Agency (IAEA) consultants’ meeting on elective nodal irradiation in lung cancer. Non-Small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys 2008;72:335-342
  25. Jeremic B, Shibamoto Y, Milicic B, Dagovic A, Nikolic N, Aleksandrovic J, Acimovic L, Milisavljevic S: Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy (Hfx RT) alone. Lung Cancer 2003;40:317-323
  26. Gauden SJ, Tripcony L: The curative treatment by radiation therapy alone of stage I non-small cell lung cancer in a geriatric population. Lung Cancer 2001;32:71-79
  27. Hayakawa K, Mitsuhashi N, Katano S: High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer. Lung Cancer 2001;32:81-88
  28. Holsti LB, Vuorinen P: Radiation reaction in the lung after continuous and split-course megavoltage radiotherapy of bronchial carcinoma. Br J Radiol 1967;40:280-284
  29. Moss WT, Haddy FJ, Sweany SK: Some factors altering the severity of acute radiation pneumonitis: variation with cortisone, heparin, and antibiotics. Radiology 1960;75:50-54
  30. Rubin P, Casarett GW: Clinical Radiation Pathology. Philadelphia, Saunders, 1968;423-470
  31. Mah K, Van Dyk J, Keane T: Acute radiation-induced pulmonary damage: a clinical study on the response to fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1987;13:179-188
  32. McDonald S, Rubin P, Phillips TL: Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995;31:1187-1203
  33. Braun SR, doPoco GA, Olson CE: Low-dose radiation pneumonitis. Cancer 1975;35:1322-1324
  34. Prasad SC: Relation between tolerance dose and treatment field size in radiation therapy. Med Phys 1978;5:430-433
  35. Garipagaoglu M, Munley MT, Hollis D: The effect of patient specific factors on radiation induced regional lung injury. Int J Radiat Oncol Biol Phys 1999;45:3331-3338
  36. Cox JD, Pajak TF, Asbell S: Interruptions of high-dose radiation therapy decrease long-term survival of favourable patients with unresectable non-small cell carcinoma of the lung: analysis of 1,244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1993;27:493-498
  37. Chen M, Jiang G-L, Fu X-L: The impact of overall treatment time on outcomes in radiation therapy for nonsmall cell lung cancer. Lung Cancer 2000;28:11-19
  38. Jeremic B, Shibamoto Y, Acimovic L, Nikolic N, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G: Second cancers occurring in patients with early stage non-small cell lung cancer treated with chest radiation therapy alone. J Clin Oncol 2001;19:1056-1063
  39. Jeremic B, Milicic B, Acimovic L, Milisavljevic S: Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early stage (I/II) non-small cell lung cancer (NSCLC). Long -term results of a phase II study. J Clin Oncol 2005;23:6873-6880

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00